Will morphing boron-based inhibitors beat the β-lactamases?
Open Access
- 1 June 2019
- journal article
- review article
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 50, 101-110
Abstract
No abstract availableKeywords
Funding Information
- Wellcome Trust
- Cancer Research UK
- Medical Research Council
- Biotechnology and Biological Research Council (BB/S50676X/1)
- National PhD Training Programme in Antimicrobial Resistance Research by the Medical Research Foundation (MRF-145-0004-TPG-AVISO)
- Innovative Medicines Initiative
This publication has 66 references indexed in Scilit:
- Small Molecule Inhibitors of AI-2 Signaling in Bacteria: State-of-the-Art and Future Perspectives for Anti-Quorum Sensing AgentsInternational Journal of Molecular Sciences, 2013
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences, 2012
- Dynamic Combinatorial Chemistry Employing Boronic Acids/Boronate Esters Leads to Potent Oxygenase InhibitorsAngewandte Chemie International Edition, 2012
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma CellsClinical Cancer Research, 2011
- Unexpected Tricovalent Binding Mode of Boronic Acids within the Active Site of a Penicillin-Binding ProteinJournal of the American Chemical Society, 2011
- Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains ofPseudomonas aeruginosaProceedings of the National Academy of Sciences, 2010
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010
- Inhibition of the Class C β-Lactamase from Acinetobacter spp.: Insights into Effective Inhibitor DesignBiochemistry, 2009
- Structure, Function, and Inhibition along the Reaction Coordinate of CTX-M β-LactamasesJournal of the American Chemical Society, 2005
- Stoffwechselprodukte von Mikroorganismen. 57. Mitteilung. BoromycinHelvetica Chimica Acta, 1967